Santa Fe, Argentina – Single Strand Biotech (SSBio), an emerging biotech company developing next-generation immunomodulatory therapies, is excited to announce its participation in BIO-Spain 2025, one of the largest biotechnology partnering events in Europe. The conference will take place in Barcelona, where SSBio will be present as part of the Argentine Pavilion showcasing leading biotech and pharmaceutical companies from the country.
This participation marks the beginning of SSBio’s fundraising roadshow, as the company continues to engage with global investors and strategic partners to support the development of its proprietary synthetic oligonucleotide drug candidate for chronic inflammatory diseases, including Inflammatory Bowel Disease (IBD).
In addition, SSBio will take part in the Trade Mission to Spain and Portugal, organized by the Ministry of Foreign Affairs of the Province of Santa Fe, during October 2025. This mission will provide the company with key opportunities to explore collaborations and expand its international presence in the European biotech ecosystem.
“BIO-Spain 2025 is the perfect stage to showcase our science and connect with investors and strategic partners interested in transformative therapies,” said Alejandro Montaner, CEO of SSBio. “Being part of the Santa Fe trade mission reinforces our commitment to positioning SSBio on the global map of biotech innovation.“